Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase…

By Dr. Matthew Watson

MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment

Read the original post:
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase...

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives - November 29th, 2024
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - November 29th, 2024
Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel - November 29th, 2024
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area - November 29th, 2024
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - November 29th, 2024
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - November 29th, 2024
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates - November 29th, 2024
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 - November 29th, 2024
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - November 29th, 2024
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis - November 29th, 2024
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq - November 29th, 2024
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia - November 29th, 2024
Celularity Inc. Announces Receipt of Nasdaq Notification - November 29th, 2024
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms - November 29th, 2024
Kane Biotech Announces Third Quarter 2024 Financial Results - November 29th, 2024
Rakovina Therapeutics Announces Private Placement Offering - November 29th, 2024
MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS) - November 29th, 2024
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million - November 29th, 2024
Panbela Provides Business Update and Reports Q3 2024 Financial Results - November 15th, 2024
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability - November 15th, 2024
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - November 15th, 2024
TFF Pharmaceuticals Announces It Will Wind Down Operations - November 15th, 2024
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - November 15th, 2024
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for... - November 15th, 2024
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - November 15th, 2024
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights - November 15th, 2024
Lowell Farms Inc. Announces Unaudited Third Quarter 2024 Financial and Operational Results - November 15th, 2024
Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons... - November 15th, 2024
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials - November 15th, 2024
Avicanna Reports Q3 2024 - November 15th, 2024
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - November 15th, 2024
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in... - November 15th, 2024
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - November 15th, 2024
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) - November 15th, 2024
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio - November 15th, 2024
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - November 15th, 2024
NINER Pharmaceutical Strengthens Global Presence with Strategic IV Fluid Supply Initiative for the U.S. and Latin American Markets - November 15th, 2024
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024 - November 15th, 2024
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer - October 21st, 2024
Phase III trial results of novel triple combination pill for hypertension published in The Lancet - October 21st, 2024
UPDATE -- Better Choice Company Chairman Issues Letter to Shareholders as Company Continues to Make Progress Towards the Closing of its SRx Health... - October 21st, 2024
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 - October 21st, 2024
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - October 21st, 2024
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - October 21st, 2024
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson - October 21st, 2024
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical... - October 21st, 2024
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress - October 21st, 2024
Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study - October 21st, 2024
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended... - October 21st, 2024
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - October 21st, 2024
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and... - October 21st, 2024
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) - October 21st, 2024
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory... - October 21st, 2024
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and... - October 21st, 2024
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare - October 21st, 2024
ViaNautis Appoints Ray Jupp as Chief Scientific Officer - October 21st, 2024
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer - October 21st, 2024
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update - October 21st, 2024
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The... - October 13th, 2024
Better Choice Company to Expand into Veterinary Medicine in 2025 Following the Acquisition of SRx Health - October 13th, 2024
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting - October 13th, 2024
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - October 13th, 2024
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting - October 13th, 2024
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 - October 13th, 2024
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024... - October 13th, 2024
Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat - October 13th, 2024
23andMe Announces 1-for-20 Reverse Stock Split - October 13th, 2024
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit - October 13th, 2024
Firefly Neuroscience to Participate in Upcoming October Investor Conferences - October 13th, 2024
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - October 13th, 2024
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing - October 13th, 2024
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - October 13th, 2024
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID - October 13th, 2024
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 - October 13th, 2024
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 - October 13th, 2024
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - October 13th, 2024
Quest PharmaTech Announces Results from AGM - October 13th, 2024
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the... - October 13th, 2024

Global News Feed commento

Comments Off | data

June 2nd, 2024

About... Dr. Matthew Watson

This author published 5872 posts in this site.

Comments are closed.

Previous post - Next post

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase…

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites